Summary

A new long-acting HIV treatment could expand options for people who have trouble taking daily pills and whose virus is resistant to some commonly used HIV drugs, according to a new UC San Francisco study. Unlike daily HIV pills, long-acting treatments can be given weeks or months apart, which can make it easier for people who struggle to take medication every day. The only approved long-acting combination pairs cabotegravir with rilpivirine . But HIV can develop resistance to rilpivirine and related drugs, limiting its use for some people.

AI summaries can be wrong sometimes—always verify important details using the source article.